Active surveillance protocol in prostate cancer in Portugal

被引:1
|
作者
Gaspar, S. R. da Silva [1 ]
Fernandes, M. [1 ]
Castro, A. [1 ]
Oliveira, T. [1 ]
Dias, J. Santos [1 ]
dos Reis, J. Palma [1 ]
机构
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Urol, Lisbon, Portugal
来源
ACTAS UROLOGICAS ESPANOLAS | 2022年 / 46卷 / 06期
关键词
Active surveillance; Prostate cancer; Watchful waiting; Portugal; MRI; Biopsy; VERSION; 2; MEN; COMPLICATIONS; MANAGEMENT; BIOPSIES;
D O I
10.1016/j.acuro.2021.01.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine clinical practice patterns in locally managing patients under an active surveillance protocol among Portuguese urologists. Introduction: Prostate cancer (PCa) is a heterogeneous disease with many prostate adeno-carcinomas being indolent and a low probability of ever causing symptoms or death. Active surveillance (AS) is a form of conservative management aimed to reduce over-treatment for low-risk PCa patients. Over the years, experience with AS has grown considerably and is now standard in some countries, however a universal protocol still does not exist. Methods: Nationwide anonymous e-survey concerning habits and practices on AS among Portu-guese urologists, that consisted of 12 questions and was sent electronically to all 368 current members of the Portuguese Urological Association. Results: 56 urologists were surveyed (15.21% answer rate), evenly distributed geographically and allocated according to years of experience as well as number of PCa patients managed monthly. The vast majority of respondents recommends AS to their patients, particularly ISUP grade 1 patients, whose PSA serum level is bellow 20ng/mL. Observance of AS programs by patients was not in question but concerns exist over psychological morbidity while harboring disease. Majority believed that international guidelines surveillance protocols were adequate and sufficient, but there are some constraints concerning availability of periodic MRIs and re -biopsy needs. Conclusions: AS seems to be sustained in urologist clinical practice, although patients still lag to adhere and choose for active treatment. AS may not be an easy choice for patients and clinicians due to uncertainty of disease progression, risk of loss to follow-up and repeated biopsies but is also a cause for anxiety, depression, uncertainty and a perception of danger. (c) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:329 / 339
页数:11
相关论文
共 50 条
  • [41] Active surveillance for localized prostate cancer
    Staerman, F.
    Peyromaure, M.
    Irani, J.
    Gaschignard, N.
    Mottet, N.
    Soulie, M.
    Salomon, L.
    PROGRES EN UROLOGIE, 2011, 21 (07): : 448 - 454
  • [42] Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols
    Kates, Max
    Tosoian, Jeffrey J.
    Trock, Bruce J.
    Feng, Zhaoyong
    Carter, H. Ballentine
    Partin, Alan W.
    BJU INTERNATIONAL, 2015, 115 (02) : 216 - 222
  • [43] The utility of prostate MRI within active surveillance: description of the evidence
    Dominique, Georgina
    Brisbane, Wayne G.
    Reiter, Robert E.
    WORLD JOURNAL OF UROLOGY, 2022, 40 (01) : 71 - 77
  • [44] Active surveillance for localized prostate cancer
    Drouin, S. J.
    Roupret, M.
    Hamdy, F.
    Mottet, N.
    PROGRES EN UROLOGIE, 2010, 20 : S181 - S185
  • [45] The evolving landscape: magnetic resonance imaging in active surveillance for prostate cancer management
    de la Parra, Irene
    Rivas, Juan Gomez
    Gutierrez, Beatriz
    Marugan, Maria Jesus
    Enikeev, Dmitry
    Somani, Bhaskar K.
    Barrera, Jeronimo
    Moreno-Sierra, Jesus
    FRONTIERS IN UROLOGY, 2024, 4
  • [46] mpMRI Interpretation in Active Surveillance for Prostate Cancer-An overview of the PRECISE score
    Harder, Felix N.
    Heming, Carolina A. M.
    Haider, Masoom A.
    ABDOMINAL RADIOLOGY, 2023, 48 (07) : 2449 - 2455
  • [47] Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN)
    Kato, Takuma
    Matsumoto, Ryuji
    Yokomizo, Akira
    Tohi, Yoichiro
    Fukuhara, Hiroshi
    Fujii, Yoichi
    Mori, Keiichiro
    Sato, Takuma
    Inokuchi, Junichi
    Hashine, Katsuyoshi
    Sakamoto, Shinichi
    Kinoshita, Hidefumi
    Inoue, Koji
    Tanikawa, Toshiki
    Utsumi, Takanobu
    Goto, Takayuki
    Hara, Isao
    Okuno, Hiroshi
    Kakehi, Yoshiyuki
    Sugimoto, Mikio
    BJU INTERNATIONAL, 2024, 134 (04) : 652 - 658
  • [48] Impact of prostate volume on the active surveillance in prostate cancer
    Beaujouan, Florent
    Bertherat, Walter
    Hammoudi, Zakaria
    Chicaud, Marie
    Descazeaud, Aurelien
    JOURNAL OF CLINICAL UROLOGY, 2024,
  • [49] MRI and active surveillance for low risk prostate cancer; [MRI en active surveillance voor laagrisicoprostaatkanker]
    van den Bergh R.C.N.
    Meijer R.P.
    Heijmink S.W.
    van der Poel H.G.
    Tijdschrift voor Urologie, 2014, 4 (8) : 185 - 191
  • [50] Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance
    Wang, Michael
    Lange, Andrew
    Perlman, David
    Qi, Ji K.
    George, Arvin K.
    Ferrante, Stephanie
    Semerjian, Alice
    Sarle, Richard L.
    Cher, Michael L. B.
    Ginsburg, Kevin B.
    PROSTATE, 2023, 83 (12) : 1141 - 1149